Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) vs Bosulif (bosutinib)

Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) vs Bosulif (bosutinib)

Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) is an asparagine-specific enzyme used as a component of a multi-agent chemotherapeutic regimen to treat acute lymphoblastic leukemia (ALL) in patients who have developed hypersensitivity to E. coli-derived asparaginase. Bosulif (bosutinib) is a tyrosine kinase inhibitor indicated for the treatment of adults with chronic, accelerated, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) who are resistant or intolerant to prior therapy. When deciding between Rylaze and Bosulif, the choice is not interchangeable as they are used for different types of leukemia and the decision should be based on the specific type and phase of leukemia diagnosed, as well as the patient's previous treatment history and any existing sensitivities or intolerances to medication.

Difference between Rylaze and Bosulif

Metric Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Bosulif (bosutinib)
Generic name Asparaginase erwinia chrysanthemi (recombinant)-rywn Bosutinib
Indications Acute lymphoblastic leukemia (ALL) as a component of a multi-agent chemotherapeutic regimen Chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy
Mechanism of action Hydrolyzes asparagine to aspartic acid and ammonia, depriving leukemia cells of asparagine which is essential for their growth Tyrosine kinase inhibitor that targets BCR-ABL, SRC family, c-KIT, PDGFR, and EPH receptors
Brand names Rylaze Bosulif
Administrative route Intramuscular or subcutaneous injection Oral
Side effects Hypersensitivity, pancreatitis, thrombosis, hemorrhage, hepatotoxicity Diarrhea, nausea, thrombocytopenia, rash, increased liver enzymes
Contraindications History of serious hypersensitivity to asparaginase erwinia chrysanthemi Hypersensitivity to bosutinib or any component of the formulation
Drug class Antineoplastic agent, enzyme Tyrosine kinase inhibitor
Manufacturer Jazz Pharmaceuticals Pfizer

Efficacy

Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn) Efficacy in Leukemia

Rylaze, also known as asparaginase Erwinia chrysanthemi (recombinant)-rywn, is a medication specifically approved by the U.S. Food and Drug Administration (FDA) for use in patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. Rylaze functions by depleting the amino acid asparagine, which leukemia cells require to grow and proliferate. By depriving them of this essential nutrient, Rylaze can inhibit the growth of leukemia cells. Clinical trials have demonstrated that Rylaze is effective in maintaining therapeutic asparaginase activity levels in patients with ALL, which is critical for the efficacy of the treatment regimen.

The efficacy of Rylaze was evaluated in a clinical study that included patients with ALL or lymphoblastic lymphoma who had either a history of hypersensitivity to E. coli-derived asparaginase or experienced silent inactivation. The primary endpoint was the achievement and maintenance of nadir serum asparaginase activity (NSAA) above the level of 0.1 U/mL. A significant proportion of patients treated with Rylaze were able to maintain this therapeutic threshold, indicating the drug's effectiveness in providing an alternative source of asparaginase enzyme activity for patients who cannot tolerate the E. coli-derived formulations.

Bosulif (Bosutinib) Efficacy in Leukemia

Bosulif, with the active ingredient bosutinib, is a tyrosine kinase inhibitor approved for the treatment of adult patients with chronic myelogenous leukemia (CML). This medication is indicated for use in patients with newly diagnosed chronic phase CML and for those with chronic, accelerated, or blast phase CML who are resistant to or intolerant of prior therapy. Bosulif works by inhibiting the Bcr-Abl kinase that promotes CML; it is effective in reducing the number of abnormal cells in this condition.

The efficacy of Bosulif for newly diagnosed chronic phase CML was established in a randomized trial comparing it to imatinib, another tyrosine kinase inhibitor. The trial measured major molecular response (MMR) rates at 12 months, complete cytogenetic response (CCyR) rates, and overall survival (OS). Bosulif demonstrated a higher MMR rate at 12 months compared to imatinib, which was statistically significant. Additionally, the drug showed a favorable response in patients who were previously treated with other tyrosine kinase inhibitors but either did not respond adequately or could not tolerate the medication. These findings substantiate the effectiveness of Bosulif as a treatment option for CML patients with different phases of the disease and treatment histories.

Regulatory Agency Approvals

Rylaze
  • Food and Drug Administration (FDA), USA
Bosulif
  • European Medical Agency (EMA), European Union
  • Food and Drug Administration (FDA), USA

Access Rylaze or Bosulif today

If Rylaze or Bosulif are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email:

Contact us
US United States 1